SZ1676 is primarily used in research and development within the pharmaceutical industry. It has shown potential as a therapeutic agent in preclinical studies, particularly in targeting specific pathways involved in disease modulation. Its application is being explored in the treatment of certain types of cancers and inflammatory conditions, where it may inhibit key proteins or enzymes responsible for disease progression. Additionally, SZ1676 is being investigated for its role in enhancing drug delivery systems, improving the efficacy and specificity of treatments. Ongoing studies aim to further understand its mechanisms and optimize its use in clinical settings.